Serum Myeloperoxidase Level in Patients with Chronic Heart Failure

Evidence suggests that the serum myeloperoxidase level has a diagnostic and predictive role in patients with chronic heart failure (CHF). We evaluated the association between the serum myeloperoxidase level and the severity and prognosis of CHF. Materials: In a prospective observational study, patients with CHF were evaluated. The myeloperoxidase serum level was measured at baseline by enzyme-linked immunosorbent assay. Transthoracic echocardiography was done at baseline and then after 6 months. History and duration of admission and also mortality were recorded during follow-up. Fifty patients at a mean age of 64.7±1.8 years (70% male) were evaluated. The mean ser into two groups of A and B with a serum myeloperoxidase level of less and more than 51 Heart Association functional class (NYHA III 20.5% vs. 27.3%; p value=0.456), left ventricular ejection fraction (30.3±10.0 vs. 29.8±10.1%; p value=0.873), systolic dysfunction (48.7% vs. 54.5%; p value=0.500), or diastolic dysfunction (38.5% vs. 63.6%; -up. The serum myeloperoxidase level was not associated with admission history or mortality. We found no significant association between the serum myeloperoxidase level and echocardiography parameters, admission history, or mortality in patients with CHF. Further studies with larger samples of patients are required in this regard.